作为疾病中药物点的短PDE4异型
Elka Kyurkchieva1, George S Baillie1
1School of Cardiovascular & Metabolic Health, University of Glasgow, G12 8QQ Glasgow, UK.
Frontiers in bioscience (Landmark edition)
|August 1, 2023
概括
固酶4 (PDE4) 酶通过循环腺单酸盐 (cAMP) 调节细胞信号传递. 本综述强调了研究不足的短PDE4异型,将其作为开发具有较少副作用的新疗法的一个有希望的目标.
科学领域:
- 分子生物学分子生物学
- 信号传输 信号传输
- 酶学 是一种酶学.
背景情况:
- 循环腺单酸盐 (cAMP) 是一个关键的第二信使,调节细胞平衡和信号转导.
- 固酶 (PDEs),特别是PDE4家族,通过催化其降解来控制cAMP水平,从而影响受体特异信号传递.
- 包括异常表达和修改在内的PDE4失调与各种疾病有关,但目前的治疗方法面临局限性.
研究的目的:
- 审查目前关于固酶4 (PDE4) 较少研究的短异构体的文献.
- 详细介绍短PDE4异型的发现,调节和疾病相关性.
- 突出短PDE4异型,作为特定治疗抑制的潜在未开发的目标.
主要方法:
- 文献综述和对PDE4异型的现有研究的综合.
- 分析PDE4长异形和短异形之间的结构和功能差异.
- 检查PDE4异型在各种疾病病理中的作用.
主要成果:
- 包括长和短异型在内的PDE4酶在产生局部cAMP梯度方面发挥着关键作用,这些梯度对于细胞信号传输至关重要.
- 目前的PDE4抑制剂主要向长异型的保存活性位点,导致非向效应和副作用.
- 短PDE4异型具有独特的结构特征,可能允许更具体的抑制剂发展.
结论:
- 短PDE4异型体代表了一种独特的酶类,具有独特的调节机制和疾病关联.
- 准短PDE4异型是一种潜在的策略,可以开发具有更好的安全概况的更有选择性的治疗方法.
- 对短PDE4异型的进一步研究是有必要的,以充分利用它们的治疗潜力.
关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.癌症 癌症 癌症 癌症 癌症慢性阻塞性肺病 慢性阻塞性肺病循环性AMP的使用情况.药物目标是药物目标.这是一种炎症炎症炎症炎症.多发性硬化症多发性硬化症基化酶是一种基化剂.简短的异形形态.创伤性脑损伤是一种创伤性脑损伤更多相关视频
08:45Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
6.3K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
189
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
189
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
01:23Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
01:26Targets for Drug Action: Overview
6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
205
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
205